Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.

Smith, Hannah L; Willmore, Elaine; Mukhopadhyay, Asima; Drew, Yvette; Curtin, Nicola J

Smith, Hannah L; Willmore, Elaine; Mukhopadhyay, Asima; Drew, Yvette; Curtin, Nicola J.

Afiliação

Smith HL; Faculty of Medical Sciences, Newcastle University Centre for Cancer, Newcastle upon Tyne NE1 7RU, UK.
Willmore E; Faculty of Medical Sciences, Newcastle University Centre for Cancer, Newcastle upon Tyne NE1 7RU, UK.
Mukhopadhyay A; Kolkata Gynecological Oncology Trials and Translational Research Group, Chittaranjan National Cancer Institute, 37 SP Mukherjee Road, Kolkata 700026, India.
Drew Y; BC Cancer Centre Vancouver and Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Curtin NJ; Faculty of Medical Sciences, Newcastle University Centre for Cancer, Newcastle upon Tyne NE1 7RU, UK.

Cancers (Basel) ; 14(22)2022 Nov 12.

Article em En | MEDLINE | ID: mdl-36428653

Palavras-chave

ATR; DDR; PARP1; durability

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google